Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations
January 2024
in “
Curēus
”
![Image of study](/images/research/bea1e8fc-2949-44a7-a8cd-5c2d48660f7f/medium/37005.jpg)
TLDR Clinicians should use social and prescription data to track trends in performance-enhancing drug use.
This study investigates the trends in interest for performance-enhancing drugs (PEDs) and related ancillary compounds, highlighting a significant rise in interest for selective androgen receptor modulators (SARMs) like RAD-140, while interest in anabolic steroids and post-cycle therapies remains stagnant or decreases. The authors suggest using social and prescription data as proxies to help clinicians better understand and adapt to these trends, given the lack of clinically relevant data and evidence-based approaches for monitoring PED use and its adverse effects.